Condition: Locally Advanced Unresectable Pancreatic Adenocarcinoma · Sponsor: Impact Biotech Ltd
This is a prospective, multicenter, non-randomized, open label light dose escalation phase I trial to evaluate the safety and preliminary efficacy of Padeliporfin vascular targeted photodynamic therapy (VTP) applied via endovascular fiber placement within a dilatation catheter, through the target artery(superior mesenteric artery (SMA), celiac artery (CA) or common hepatic artery (CHA)). The investigators will evaluate safety and preliminary efficacy of Padeliporfin VTP administered endovascularly using light dose escalation.
This description comes directly from the study's public registry record.
Eyal Morag, MD · +972 54 2056619 · eyal.morag@impactbiotech.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| University of California Irvine | Irvine, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05919238